Tonix to Present Programs for PTSD, Fibromyalgia Drug Candidate at European Conference

Tonix to Present Programs for PTSD, Fibromyalgia Drug Candidate at European Conference
Tonix Pharmaceuticals, a company dedicated to developing next-gen medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced its Executive Vice President of Commercial Planning and Development, Ronald Notvest, Ph.D., MBA, will present at the 10th Annual BIO Europe Spring Conference in Sweden. Notvest’s presentation will provide a corporate update and a general overview of Tonix Pharmaceuticals’ fibromyalgia and PTSD clinical programs. Tonix is currently evaluating the drug candidate TNX-102 SL, an FDA Investigational New Drug, in:

One comment

  1. Marnie Kennedy says:

    I have had Fibro since I was 8years old. At 44 I now also have Chronic Fatigue, Mysofacial pain syndrome, DDD, DJD and Raynod syndrome. I would love to be involved in your exploration in finding a treatment that works.

Leave a Comment

Your email address will not be published. Required fields are marked *